Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX) and Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)

Praxis Precision Medicines ( ($PRAX) ) has provided an announcement. On May 7, 2026, Praxis Precision Medicines reported first-quarter 2026 results...

Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines’ ...

Praxis Precision Medicines Maps High-Stakes Launch Path

In a report released today, Laura Chico from Wedbush maintained a Sell rating on Praxis Precision Medicines, with a price target of $166.00. Chico ...

Wedbush Remains a Sell on Praxis Precision Medicines (PRAX)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $1,245.00. According to ...

H.C. Wainwright Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Praxis Precision ...

Current Quarter	$-3.88	Next Quarter	$-3.89
Current Year	$-14.79	Next Year	$-10.95
QoQ Growth	-0.3%	YoY Growth	+26.0%
3Y EPS CAGR	+42.1%	Target Price	$652.18
Consensus	Buy	Upside	+86.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$350.60	+2.05%	384.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$350.60	+2.0%	384.66K
3
4
5
6

PRAX

PRAX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel